ARWR Arrowhead Pharmaceuticals, Inc. Stock Quote

Your browser is no longer supported. Please, upgrade your browser.

publish chart | save to portfolio | create alert

ARWR [NASD]

Arrowhead Pharmaceuticals, Inc.

Healthcare | Biotechnology | USA

statements

Index	-	P/E	449.60	EPS (ttm)	0.10	Insider Own	4.50%	Shs Outstand	101.65M	Perf Week	0.70%
Market Cap	4.53B	Forward P/E	-	EPS next Y	-0.97	Insider Trans	-5.22%	Shs Float	99.05M	Perf Month	27.14%
Income	9.50M	PEG	61.34	EPS next Q	-0.11	Inst Own	65.50%	Short Float	8.48%	Perf Quarter	31.41%
Sales	139.00M	P/S	32.56	EPS this Y	205.90%	Inst Trans	1.30%	Short Ratio	6.88	Perf Half Y	-24.48%
Book/sh	4.86	P/B	9.16	EPS next Y	-90.20%	ROA	2.10%	Target Price	62.10	Perf Year	69.30%
Cash/sh	3.03	P/C	14.71	EPS next 5Y	7.33%	ROE	2.60%	52W Range	19.51 - 73.72	Perf YTD	-29.83%
Dividend	-	P/FCF	-	EPS past 5Y	20.60%	ROI	24.90%	52W High	-39.62%	Beta	1.83
Dividend %	-	Quick Ratio	5.90	Sales past 5Y	295.20%	Gross Margin	-	52W Low	128.14%	ATR	2.14
Employees	134	Current Ratio	5.90	Sales Q/Q	-51.10%	Oper. Margin	0.80%	RSI (14)	65.85	Volatility	3.95% 6.18%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-180.10%	Profit Margin	6.90%	Rel Volume	0.59	Prev Close	45.15
Shortable	Yes	LT Debt/Eq	0.00	Earnings	May 07 AMC	Payout	0.00%	Avg Volume	1.22M	Price	44.51
Recom	2.00	SMA20	11.05%	SMA50	20.81%	SMA200	7.19%	Volume	722,368	Change	-1.42%

May-13-20

Initiated

RBC Capital Mkts

Outperform

$62

May-08-20

Upgrade

Oppenheimer

Perform → Outperform

$58

Apr-15-20

Upgrade

Cantor Fitzgerald

Neutral → Overweight

$55 → $60

Mar-24-20

Upgrade

SVB Leerink

Underperform → Mkt Perform

$29

Mar-17-20

Initiated

Goldman

Neutral

$45

Jan-21-20

Initiated

SVB Leerink

Underperform

$32

Dec-13-19

Initiated

Oppenheimer

Perform

Nov-29-19

Reiterated

Chardan Capital Markets

Buy

$45 → $81

Nov-27-19

Reiterated

B. Riley FBR

Buy

$59 → $83

Nov-25-19

Upgrade

Robert W. Baird

Neutral → Outperform

$70

Oct-24-19

Downgrade

Robert W. Baird

Outperform → Neutral

$39

Oct-22-19

Reiterated

Chardan Capital Markets

Buy

$32 → $45

Oct-03-19

Initiated

Robert W. Baird

Outperform

$39

Sep-07-18

Upgrade

B. Riley FBR

Neutral → Buy

$18 → $19

Sep-06-18

Reiterated

Chardan Capital Markets

Buy

$17.50 → $24.50

Aug-08-18

Reiterated

Cantor Fitzgerald

Overweight

$13 → $18

Jul-02-18

Reiterated

Chardan Capital Markets

Buy

$9.50 → $16

May-09-18

Upgrade

Cantor Fitzgerald

Neutral → Overweight

$13

Mar-27-18

Initiated

Jefferies

Buy

$10

Feb-12-18

Reiterated

Cantor Fitzgerald

Neutral

$2 → $5

Jul-09-20 08:19AM	What Kind Of Shareholders Hold The Majority In Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) Shares? Simply Wall St.
07:30AM	Arrowhead Pharmaceuticals to Host Key Opinion Leader Webinar on ARO-ENaC for Treatment of Cystic Fibrosis Business Wire
Jul-08-20 04:00PM	Arrowhead Pharmaceuticals to Webcast Fiscal 2020 Third Quarter Results Business Wire
10:13AM	Here's Why Arrowhead Pharmaceuticals Stock Jumped 34% in June Motley Fool
Jun-16-20 09:46PM	Is Arrowhead Pharmaceuticals Inc. (ARWR) A Good Stock To Buy? Insider Monkey +7.62%
09:30AM	ARWR: Multiple Shots on Goal for RNAi Platform Zacks Small Cap Research
Jun-02-20 12:35PM	Will Johnson & Johnson Acquire Arrowhead Pharmaceuticals? Motley Fool
May-30-20 06:35PM	Edited Transcript of ARWR earnings conference call or presentation 7-May-20 8:30pm GMT Thomson Reuters StreetEvents
May-28-20 07:30AM	Arrowhead Pharmaceuticals to Participate in Upcoming June 2020 Conferences Business Wire
May-24-20 10:10AM	Is Arrowhead Pharmaceuticals a Buy? Motley Fool
May-22-20 11:34AM	Arrowhead Pharmaceuticals Is Likely to See a Trading Range Market Ahead TheStreet.com
May-19-20 07:02AM	Will Arrowhead Pharmaceuticals Be a Biotech Winner? Motley Fool
May-10-20 08:20AM	Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Second-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year Simply Wall St.
May-08-20 09:30PM	Arrowhead Pharmaceuticals, Inc (ARWR) Q2 2020 Earnings Call Transcript Motley Fool
May-07-20 04:00PM	Arrowhead Pharmaceuticals Reports Fiscal 2020 Second Quarter Results Business Wire
May-01-20 04:00PM	Arrowhead Pharmaceuticals to Participate in Upcoming May 2020 Conferences Business Wire -5.43%
04:00PM	Arrowhead Pharmaceuticals Announces Retirement of COO Bruce Given Business Wire
Apr-30-20 07:52AM	Is Arrowhead Pharmaceuticals Close to a Cure for HBV? Motley Fool -5.75%
Apr-22-20 07:30AM	Arrowhead Pharmaceuticals to Webcast Fiscal 2020 Second Quarter Results Business Wire
Apr-20-20 06:31AM	Arrowhead Pharmaceuticals' (NASDAQ:ARWR) Incredible 2370% Share Price Run Shows What Is Possible With Stocks Simply Wall St. +6.40%
Apr-10-20 07:30AM	Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1/2a Study of ARO-ENaC for Treatment of Cystic Fibrosis Business Wire
Apr-06-20 06:26PM	Alnylam, Dicerna Join Forces to Take on Arrowhead GuruFocus.com +10.80%
10:30AM	Former gene-silencing rivals bury the hatchet with new partnership American City Business Journals
Mar-20-20 02:15PM	Hedge Funds Have Never Been This Bullish On Arrowhead Pharmaceuticals, Inc. (ARWR) Insider Monkey +6.88%
Mar-18-20 08:00PM	Bragar Eagel & Squire is Investigating Certain Officers and Directors of comScore, Mammoth Energy, AMC Entertainment, and Arrowhead Pharmaceuticals and Encourages Investors to Contact the Firm GlobeNewswire -6.42%
Mar-17-20 04:10PM	Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4) Business Wire
04:10PM	Arrowhead Pharmaceuticals Announces Precautionary Measures to Mitigate Effects of Novel Coronavirus (COVID-19) Spread Business Wire
Mar-15-20 08:30AM	Is Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) CEO Salary Justified? Simply Wall St.
Mar-10-20 04:16PM	Bragar Eagel & Squire is Investigating Certain Officers and Directors of comScore, Zuora, AMC Entertainment, and Arrowhead Pharmaceuticals and Encourages Investors to Contact the Firm GlobeNewswire
Mar-03-20 07:30AM	Arrowhead Pharmaceuticals Initiates Phase 1/2 Study of ARO-HSD in Normal Healthy Volunteers and Patients with NASH or Suspected NASH Business Wire
Mar-02-20 04:00PM	Arrowhead Pharmaceuticals to Participate in Upcoming March 2020 Conferences Business Wire
Feb-13-20 04:47PM	Bragar Eagel & Squire is Investigating Certain Officers and Directors of Zuora, Arrowhead Pharmaceuticals, ResMed, and Covetrus and Encourages Investors to Contact the Firm GlobeNewswire
Feb-12-20 09:37PM	Edited Transcript of ARWR earnings conference call or presentation 5-Feb-20 9:30pm GMT Thomson Reuters StreetEvents
Feb-07-20 09:36AM	Should First Trust Mid Cap Growth AlphaDEX ETF (FNY) Be on Your Investing Radar? Zacks
Feb-06-20 07:47AM	The Daily Biotech Pulse: Tonix Slumps On Failed Study, Applied Genetic Announces Offering, Beam Therapeutics, PPD Price IPOs Benzinga -5.99%
Feb-05-20 04:00PM	Arrowhead Reports Interim Clinical Data on Cardiometabolic Candidates ARO-APOC3 and ARO-ANG3 Business Wire
04:00PM	Arrowhead Pharmaceuticals Reports Fiscal 2020 First Quarter Results Business Wire
07:43AM	The Daily Biotech Pulse: Merck Spins Off Slow-Growth Businesses, ZioPharm Announces Offering, PhaseBio Data Benzinga
Feb-03-20 01:06PM	Arrowhead (ARWR) to Report Q1 Earnings: What's in the Cards? Zacks
Jan-24-20 05:31AM	Is Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) A Volatile Stock? Simply Wall St.
Jan-22-20 04:29PM	Will These Biotechs Rival A Top-Notch Stock In High Triglycerides? Investor's Business Daily
07:30AM	Arrowhead Pharmaceuticals to Webcast Fiscal 2020 First Quarter Results Business Wire
Jan-21-20 04:30PM	Why This Top-Notch Biotech Stock Just Plunged By Double Digits Investor's Business Daily -15.65%
Jan-16-20 03:55PM	SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Arrowhead Pharmaceuticals, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors PR Newswire
Jan-11-20 08:00AM	These Four Stocks Are In Buy Range Before Key Healthcare Conference Investor's Business Daily
Jan-10-20 11:51AM	3 Biotech Stocks to Bank on for Buyouts in 2020 InvestorPlace
Jan-06-20 07:30AM	Arrowhead Pharmaceuticals Appoints James Hassard as Chief Commercial Officer Business Wire
Jan-02-20 08:00AM	Biotech Stocks Are On Fire Who's Leading The Profit Pack For 2020? Investor's Business Daily
Dec-27-19 06:06PM	Best Stocks 2019: Innovation, As Usual, Wins The Day Or Even The Year Investor's Business Daily
Dec-26-19 05:27AM	Should First Trust Mid Cap Growth AlphaDEX Fund (FNY) Be on Your Investing Radar? Zacks
Dec-24-19 10:00AM	What was the top stock of 2019? And should it be in your retirement account? MarketWatch
Dec-23-19 10:21AM	Arrowhead Pharma Investors Should Aim for Taking Profits TheStreet.com
08:00AM	Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)? Zacks
Dec-20-19 07:30AM	Arrowhead Pharmaceuticals Doses First Patient in AROAAT2002 Open Label Phase 2 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease Business Wire -6.19%
Dec-16-19 10:55PM	Edited Transcript of ARWR earnings conference call or presentation 25-Nov-19 9:30pm GMT Thomson Reuters StreetEvents
04:15PM	Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4) Business Wire
07:30AM	Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1 Study of ARO-HSD for Treatment of Alcohol and Nonalcohol Related Liver Disease Business Wire
Dec-13-19 06:12PM	Live Nation Entertainment, Zebra Technologies, STERIS Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600 PR Newswire
07:30AM	Arrowhead Pharmaceuticals Appoints Marianne De Backer to Board of Directors Business Wire
Dec-11-19 03:46PM	Did Hedge Funds Drop The Ball On Arrowhead Research Corp (ARWR) ? Insider Monkey
07:30AM	Arrowhead Pharmaceuticals Files IND for Phase 1b Study of ARO-HIF2 for Treatment of Clear Cell Renal Cell Carcinoma Business Wire
Dec-06-19 04:01PM	Arrowhead Pharmaceuticals Closes Underwritten Public Offering with Gross Proceeds of $266.8 Million Business Wire
Dec-04-19 06:00AM	Arrowhead Pharmaceuticals Announces Pricing of Underwritten Public Offering of Common Stock Business Wire
Dec-03-19 09:26AM	Where to Buy Booming Biotech ETFs Investopedia +8.42%
06:55AM	Should First Trust Mid Cap Growth AlphaDEX Fund (FNY) Be on Your Investing Radar? Zacks
Dec-02-19 04:48PM	This Highly Rated Biotech Company Just Tumbled 13% On A Public Offering Investor's Business Daily -13.26%
04:05PM	Arrowhead Pharmaceuticals Announces Proposed Underwritten Offering of Common Stock Business Wire
02:57PM	7 Exciting Biotech Stocks to Buy Now InvestorPlace
Nov-29-19 01:23PM	This Biotech With 488% Growth In 2019 Just Gained A Price-Target Boost Investor's Business Daily +5.78%
09:52AM	Biotech Arrowhead Stocks Surge Will Continue, Analyst Says Barrons.com
Nov-28-19 08:07AM	Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)? Zacks
Nov-27-19 07:26AM	The Daily Biotech Pulse: Tonix Says No Surprises In FDA Meeting Minutes, Aravive Offering, FDA Nod For Qiagen Benzinga
04:55AM	Arrowhead Pharmaceuticals, Inc. Just Missed Earnings And Its EPS Looked Sad - But Analysts Have Updated Their Models Simply Wall St.
Nov-26-19 04:00PM	Arrowhead Pharmaceuticals to Participate in Upcoming December 2019 Conferences Business Wire +18.79%
Nov-25-19 04:00PM	Arrowhead Pharmaceuticals Reports Fiscal Year 2019 Results Business Wire +15.83%
10:27AM	Novartiss Deal for Medicines Company Is Good News for 2 More Stocks Barrons.com
Nov-18-19 09:32AM	Arrowhead Presents New Clinical Data on Cardiometabolic Candidates ARO-APOC3 and ARO-ANG3 at AHA Scientific Sessions 2019 Business Wire
Nov-15-19 07:30AM	Arrowhead Pharmaceuticals Announces Planned Management Transition Business Wire
Nov-13-19 02:12PM	Arrowhead Shares Are Still Alerting Big Buy Signals Investopedia +7.15%
Nov-11-19 07:30AM	Arrowhead Pharmaceuticals to Webcast Fiscal 2019 Year End Results Business Wire
06:29AM	Should First Trust Mid Cap Growth AlphaDEX Fund (FNY) Be on Your Investing Radar? Zacks
Nov-08-19 04:13PM	Why It Could Soon Be Time To Take Profits In This Highflying Biotech Stock Investor's Business Daily +6.31%
08:00AM	Arrowhead and Collaborator Janssen Present Phase 2 Clinical Data for Investigational Hepatitis B Regimens at The Liver Meeting® 2019 Business Wire
Nov-06-19 06:38AM	Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)? Zacks
Oct-31-19 12:15PM	Arrowhead Pharmaceuticals Presents Preclinical Data on ARO-ENaC at the North American Cystic Fibrosis Conference Business Wire
06:30AM	Dicerna ropes in Roche on gene-silencing deal worth up to $1.67B American City Business Journals
Oct-30-19 08:41AM	Best Growth Stocks for November 2019 Investopedia
Oct-26-19 07:51AM	The Arrowhead Pharmaceuticals (NASDAQ:ARWR) Share Price Is Up 557% And Shareholders Are Delighted Simply Wall St.
Oct-23-19 01:25PM	Hedge Funds Have Never Been More Bullish On Arrowhead Pharmaceuticals, Inc. (ARWR) Insider Monkey
Oct-18-19 04:38PM	Biotech Says It Hurdled A Genetic Barrier, But Shares Gave Up A Breakout Investor's Business Daily
11:10AM	Arrowhead Pharmaceuticals Is Flying Higher on the Charts TheStreet.com
07:30AM	Arrowhead Pharmaceuticals Hosts R&D Day on Emerging Pipeline of RNAi Therapeutics Business Wire
Oct-04-19 12:11PM	Medical stocks on the move: AbbVie, Arrowhead Pharmaceuticals and Zynex MarketWatch
Oct-02-19 04:15PM	Arrowhead Pharmaceuticals to Host R&D Day on Emerging Pipeline of RNAi Therapeutics Business Wire
Sep-30-19 04:00PM	Arrowhead Pharmaceuticals to Participate in Upcoming October 2019 Conferences Business Wire
Sep-27-19 09:15AM	ARWR: Broad-Based Pipeline Progress. Three Pivotal Studies, Value-Inflection Opportunities In View. Zacks Small Cap Research
Sep-20-19 04:00PM	Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4) Business Wire
10:19AM	Is Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) CEO Paid Enough Relative To Peers? Simply Wall St.
Sep-16-19 03:00AM	Arrowhead Pharmaceuticals Presents Initial Top-Line Clinical Data and Preclinical Data on RNAi Candidates ARO-APOC3 and ARO-ANG3 Business Wire
Sep-09-19 06:51AM	Should First Trust Small Cap Growth AlphaDEX Fund (FYC) Be on Your Investing Radar? Zacks -8.92%

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in Phase I clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase I clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD for treating liver diseases; ARO-ENaC to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; and ARO-HIF2 for the treatment of clear cell renal cell carcinoma. It is also involved in the development of JNJ-3989, a third-generation subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; AMG 890 to reduce production of apolipoprotein A; and ARO-AMG1 for treating undisclosed genetically-validated cardiovascular target. Arrowhead Pharmaceuticals, Inc. has a license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop RNAi therapeutics. The company was formerly known as Arrowhead Research Corporation and changed its name to Arrowhead Pharmaceuticals, Inc. in April 2016. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Anzalone Christopher Richard	Chief Executive Officer	Jun 25	Sale	38.81	100,000	3,881,017	2,605,237	Jun 26 06:02 PM
De Backer Marianne	Director	Jun 15	Buy	31.33	500	15,665	16,500	Jun 24 06:10 PM
PERRY MICHAEL S	Director	May 14	Option Exercise	3.70	77,000	285,200	85,000	May 18 06:27 PM
PERRY MICHAEL S	Director	May 12	Sale	35.83	36,000	1,289,891	8,000	May 13 06:48 PM
Waddill William D.	Director	May 11	Sale	36.54	26,000	950,040	28,000	May 13 06:45 PM
GIVEN BRUCE D	Chief Operating Officer	Apr 28	Option Exercise	8.61	4,197	36,131	855,831	Apr 29 07:19 PM
GIVEN BRUCE D	Chief Operating Officer	Apr 28	Sale	40.00	5,101	204,040	850,730	Apr 29 07:19 PM
GIVEN BRUCE D	Chief Operating Officer	Apr 27	Option Exercise	5.19	200	1,038	851,934	Apr 29 07:19 PM
GIVEN BRUCE D	Chief Operating Officer	Apr 27	Sale	40.00	300	12,000	851,634	Apr 29 07:19 PM
GIVEN BRUCE D	Chief Operating Officer	Apr 20	Option Exercise	8.14	16,256	132,286	875,249	Apr 22 07:00 PM
GIVEN BRUCE D	Chief Operating Officer	Apr 20	Sale	40.00	23,515	940,600	851,734	Apr 22 07:00 PM
De Backer Marianne	Director	Apr 15	Buy	35.40	500	17,700	16,000	Jun 24 06:10 PM
GIVEN DOUGLAS B	Director	Apr 14	Sale	36.89	25,000	922,250	155,925	Apr 16 07:47 PM
De Backer Marianne	Director	Mar 16	Buy	23.94	500	11,970	15,500	Jun 24 06:10 PM
De Backer Marianne	Director	Mar 12	Buy	24.80	500	12,400	15,000	Jun 24 06:10 PM
De Backer Marianne	Director	Mar 11	Buy	28.60	500	14,300	14,500	Jun 24 06:10 PM
De Backer Marianne	Director	Feb 28	Buy	34.39	500	17,195	14,000	Jun 24 06:10 PM
De Backer Marianne	Director	Feb 27	Buy	35.07	500	17,535	13,500	Jun 24 06:10 PM
Myszkowski Kenneth Allen	Chief Financial Officer	Feb 25	Option Exercise	8.84	43,445	384,145	427,668	Feb 27 05:41 PM
Myszkowski Kenneth Allen	Chief Financial Officer	Jan 21	Option Exercise	5.19	33,351	173,092	424,536	Jan 23 06:15 PM
Myszkowski Kenneth Allen	Chief Financial Officer	Jan 21	Sale	49.44	40,313	1,992,925	384,223	Jan 23 06:15 PM
De Backer Marianne	Director	Jan 13	Buy	54.95	500	27,475	13,000	Jun 24 06:10 PM
GIVEN BRUCE D	Chief Operating Officer	Jan 06	Sale	60.13	35,613	2,141,285	858,993	Jan 08 06:35 PM
O'Brien Patrick	General Counsel	Jan 06	Sale	60.12	14,625	879,261	258,375	Jan 08 06:33 PM
Myszkowski Kenneth Allen	Chief Financial Officer	Jan 06	Sale	60.11	20,000	1,202,201	391,185	Jan 08 06:31 PM
Anzalone Christopher Richard	Chief Executive Officer	Dec 24	Sale	63.50	83,333	5,291,646	1,805,237	Dec 27 04:54 PM
Anzalone Christopher Richard	Chief Executive Officer	Dec 13	Sale	66.73	83,333	5,560,489	1,888,570	Dec 13 06:35 PM
Anzalone Christopher Richard	Chief Executive Officer	Dec 12	Sale	67.50	100,000	6,749,630	1,971,903	Dec 13 06:35 PM
Anzalone Christopher Richard	Chief Executive Officer	Dec 03	Sale	61.58	12,033	740,952	2,071,903	Dec 04 06:48 PM
Anzalone Christopher Richard	Chief Executive Officer	Dec 02	Sale	69.15	37,967	2,625,570	2,083,936	Dec 04 06:48 PM
Myszkowski Kenneth Allen	Chief Financial Officer	Nov 05	Option Exercise	5.19	12,649	65,648	326,185	Nov 07 06:45 PM
Myszkowski Kenneth Allen	Chief Financial Officer	Nov 01	Option Exercise	7.75	37,884	293,601	351,420	Nov 01 07:32 PM
Myszkowski Kenneth Allen	Chief Financial Officer	Nov 01	Sale	40.85	37,884	1,547,378	313,536	Nov 01 07:32 PM
Anzalone Christopher Richard	Chief Executive Officer	Oct 10	Option Exercise	5.20	56,325	292,890	2,178,228	Oct 11 07:31 PM
Anzalone Christopher Richard	Chief Executive Officer	Oct 10	Sale	31.83	56,325	1,792,825	2,121,903	Oct 11 07:31 PM
Anzalone Christopher Richard	Chief Executive Officer	Sep 25	Sale	28.25	20,000	565,000	2,121,903	Sep 27 09:16 PM
Anzalone Christopher Richard	Chief Executive Officer	Sep 24	Option Exercise	5.10	66,645	339,890	2,208,548	Sep 24 09:12 PM
Anzalone Christopher Richard	Chief Executive Officer	Sep 24	Sale	28.20	66,645	1,879,240	2,141,903	Sep 24 09:12 PM
Anzalone Christopher Richard	Chief Executive Officer	Sep 23	Option Exercise	5.10	41,755	212,951	2,183,658	Sep 24 09:12 PM
Anzalone Christopher Richard	Chief Executive Officer	Sep 23	Sale	29.04	41,755	1,212,565	2,141,903	Sep 24 09:12 PM
Anzalone Christopher Richard	Chief Executive Officer	Sep 20	Option Exercise	5.10	4,250	21,675	2,146,153	Sep 24 09:12 PM
Anzalone Christopher Richard	Chief Executive Officer	Sep 20	Sale	29.00	4,250	123,250	2,141,903	Sep 24 09:12 PM
PERRY MICHAEL S	Director	Sep 11	Sale	30.00	85,000	2,550,000	36,000	Sep 11 08:09 PM
PERRY MICHAEL S	Director	Sep 09	Sale	28.90	100,000	2,890,000	121,000	Sep 11 08:09 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience